Blog of the website «TechCrunch» Прогноз погоды

People

John Smith

John Smith, 48

Joined: 28 January 2014

Interests: No data

Jonnathan Coleman

Jonnathan Coleman, 32

Joined: 18 June 2014

About myself: You may say I'm a dreamer

Interests: Snowboarding, Cycling, Beer

Andrey II

Andrey II, 41

Joined: 08 January 2014

Interests: No data

David

David

Joined: 05 August 2014

Interests: No data

David Markham

David Markham, 65

Joined: 13 November 2014

Interests: No data

Michelle Li

Michelle Li, 41

Joined: 13 August 2014

Interests: No data

Max Almenas

Max Almenas, 53

Joined: 10 August 2014

Interests: No data

29Jan

29Jan, 31

Joined: 29 January 2014

Interests: No data

s82 s82

s82 s82, 26

Joined: 16 April 2014

Interests: No data

Wicca

Wicca, 36

Joined: 18 June 2014

Interests: No data

Phebe Paul

Phebe Paul, 26

Joined: 08 September 2014

Interests: No data

Артем Ступаков

Артем Ступаков, 93

Joined: 29 January 2014

About myself: Радуюсь жизни!

Interests: No data

sergei jkovlev

sergei jkovlev, 59

Joined: 03 November 2019

Interests: музыка, кино, автомобили

Алексей Гено

Алексей Гено, 8

Joined: 25 June 2015

About myself: Хай

Interests: Интерес1daasdfasf, http://apple.com

ivanov5056 Ivanov

ivanov5056 Ivanov, 69

Joined: 20 July 2019

Interests: No data



Main article: Health

<< Back Forward >>
Topics from 1 to 10 | in all: 60

Fertility startup Mojo wants to take the trial and error out of IVF

14:00 | 18 November

Fertility tech startup Mojo is coming out of stealth to announce a €1.7 million (~$1.8M) seed round of funding led by Nordic seed fund Inventure. Also participating are Doberman and Privilege Ventures (an investor in Ava), plus a number of angel investors including Josefin Landgard (founder and ex-CEO of Kry) and Hampus Jakobsson (partner at BlueYard, BA in Clue & Kind.app).

Mojo’s mission, says co-founder and CEO Mohamed Taha, is to make access to fertility treatment more affordable and accessible by using AI and robotics technology to assist in sperm and egg quality analysis, selection and fertilization to reduce costs for clinics. Only by reducing clinics’ costs will the price fall for couples, he suggests.

“What the AI does in our technology stack from now until our roadmap is completed, product wise, is to look at sperm, look at eggs, look at data and ensure that the woman or the couple get precise treatment or the precise embryo that yields healthy baby,” he tells TechCrunch. “The role of robotics is to ensure that the manipulations/procedures are done precisely and at reduced time compared to nowadays, and also accurately.”

The idea for the business came to Taha after he was misdiagnosed with a kidney condition while still a student. His doctor suggested freezing his sperm as a precaution against deterioration in case he wanted to father a child in the future, so he started having regular sperm tests. “I was super annoyed with one particular fact,” he says of this. “Every time I do a sperm test I get a different result.”

After speaking to doctors the consensus view of male fertility he heard was “I shouldn’t care about my fertility — worst case scenario all that they need from me is one sperm”. He was told it would be his future partner who would be put on IVF to “take the treatment for me”. Doctors also told him there was little research into male fertility, and therefore into sperm quality — such as which sperm might yield a healthy baby or could result in a miscarriage. And after learning about what IVF entailed, Taha says it struck him as a “tough” deal for the woman.

“It’s completely blackbox,” he says of male fertility. “I also learned that in terms of IVF or ART [assisted reproductive technologies] everything, pretty much, is done manually. And everything, pretty much, also is done at random — you select a random sperm, they fertilize it with a random egg. Hopefully the technician who’s doing it manually knows his or her job. And in the end there’s going to be an embryo that will be implanted.”

He says he was also struck by the fact the ‘trial and error’ process only works 25% of the time in high end laboratories, yet can prospective parents between €40,000-€100,000 for each round of treatment. “This is where the idea of the company came from,” he adds. Mojo’s expectation for their technology is that it will be able to increase IVF success rates to 75% by 2030.

The team started work in 2016 as a weekend project during their PhDs. Taha initially trained as an electrical engineer before going on to do a PhD in nanotechnology, investigating new and affordable materials for use as biosensors. It was the microscopes and robotic arms that he and his co-founders, Fanny Chesa, Tobias Boecker, Daniel Thomas, were using in the labs to examine nanoparticles and select specific particles for insertion into other media that led them to think why not adapt this type of technology for use in fertility clinics — as an alternative to purely manual selection and fertilization.

“We just completely automate everything to ensure that the procedure is done faster, better and at the same time more reliably,” Taha says of the concept for Mojo. “No randomness. Understand the good from the bad.”

That — at least — is the theory. To be clear, they don’t yet have their proposition robustly proved out nor productized at this stage. Their intended first product, called Mojo Pro, is still pending certification as a medical device in the EU, for example. But the plan, should everything go to plan, is to get it to market next summer, starting in the UK.

This product, a combination of microscopy hardware and AI software, will be sold to fertility clinics (under a subscription model) to offer an analysis service consisting of a sperm count and quality check — as a first service for couples to determine whether or not the man has a fertility problem.

Initially, Mojo’s computer vision analysis system is focused on sperm counts, automating what Taha says is currently a manual process, as well as assessing some basic quality signals — such as the speed and morphology of the sperm. For example, a sperm with two heads or two tails would be an easy initial judgement call to weed out as “bad”, he suggests.

“The first product is to look at the sperm and say if this man experiences infertility or not. So we have a smart microscopy — built custom in-house. And this is where the element of the robotics comes in,” he explains. “At the same time we put on it an AI that looks at a moving sperm sample. Then, through looking at this, the system on Mojo Pro will tell us what is the sperm count, what is the sperm mobility (how fast they move) and what is the predominant shape of the sperm.

“The second part is the selection of the sperm [i.e. if the sample is needed for IVF]. Now we ensure that good sperm is being selected. This microscopy will look at the same and visually will guide the embryologist to pick the good sperm — that’s highlighted around, for example, by a green box. Good sperm have green boxes around them, bad sperm have red boxes around them so they can pick up through their current techniques the sperm that are highlighted green.”

Mojo

Based on internal testing of Mojo Pro the system has achieved 97% of the accuracy of a manual sperm count so far, per Taha, who says further optimization is planned.

Though he admits there’s no standardization of sperm counts in the fertility industry — which means such comparative metrics offer limited utility, given the lack of robust benchmarks.

“The way we are going with this is we’re really choosing the best of the best practitioners and we are just comparing our work against them for now,” is the claim. (Mojo’s lab partner for developing the product is TDL.)

“We will try to introduce new standards for ourselves,” he adds.

The current research focus is: “What are the visuals to make sure the sperm is good or bad; how to actually measure the sperm sample, the sperm count; in terms of morphology… how we can incorporate a protocol that can be the gold standard of computer vision or AI looking at sperm?”

The wider goal for the business is to understand much more about the role that individual sperm and eggs play in yielding a healthy (or otherwise) embryo and baby.

Taha says the team’s ultimate goal is “automating the fertilization process”, again with the help of applied AI and robotics (and likely also incorporating genetic testing to screen for diseases).

He points out that in many markets couples are choosing to conceive later in life. The big vision, therefore, is to develop new assisted reproductive technologies that can support older couples to conceive healthy babies.

“Generally speaking we leave our fertility to chance — which is sex… So there’s a little bit of randomness in the process. This doesn’t necessarily mean it’s bad — it’s how the body functions. But when you hit later ages, 30 or 40, we face biological deficiencies which means the quality of the eggs are not good any more, the quality of the sperm might not be good any more, if fertilization happens with old gametes… you are not sure there is a healthy baby. So we need technology to play a role here.

“Imagine a couple at the age of 40 who want to conceive a baby ten, twelve years from now. What happens if this couple have the possibility of the sperm of the man to be shipped somewhere, the egg of the woman to be shipped somewhere and they get fertilized using high end technology, and they get informed once the embryo is ready to be implanted. This is where we believe the consumer game will be in the future,” he says.

“We envisage ourselves going from just working with clinics in the coming ten years… making our AI and our robotics really flawless at manipulation, and then we are envisaging of having as consumer-facing way where we ensure people have healthy babies. Not necessarily this will be a clinic but it will be somehow where fertilization will happen in our facilities.”

“I’m not speaking about super humans or designer babies,” he adds. “I’m speaking about ensuring at a later stage of the conception journey to have a healthy baby. And this is where we see ART can actually be the way to procreate at later stages in order to ensure that the baby is healthy then there should be new technologies that just give you a healthy baby — and not mess up with your body.”

Of course this is pure concept right now. And Taja concedes that Mojo doesn’t even have data to determine “good” sperm from “bad” — beyond some basic signifiers.

But once samples start flowing via customers of the first product they expect to be able to start gathering data (with permission) to support further research into the role played by individual sperm and eggs in reproduction — looking at the whole journey from sperm and egg selection through to embryo and baby.

Though getting permission for all elements of the research they hope to do may be one potential barrier.

“Once the first module is in the market we will be collecting data,” he says. “And this data that we’ll be collecting will go and be associated with the live births or the treatment outcome. And with that we’ll understand more and more what is a good sperm, what is a bad sperm.

“But we need to start from somewhere. And this somewhere right now what we’re relying on is the knowledge that good practitioners have in the field.”

Taha says he and his co-founders actively started building the company in January 2018, taking in some angel investment, along with government grants from France and the EU’s Horizon 2020 research pot.

They’ve been building the startup out of Lyon, France but the commercial team will shortly be moving to the UK ahead of launching Mojo Pro.

In the short term the hope is to attract clinics to adopt the Mojo Pro subscription service as a way for them to serve more customers, while potentially helping couples reduce the number of IVF cycles they have to go. Longer term the bet is that changing lifestyles will only see demand for data-fuelled technology-assisted reproduction grow.

“Now we help streamline laboratory processes in order to help the 180M people who have fertility problems have access to fertility at an affordable price and reliable manner but also we have an eye on the future — what happens when genetic testing… [plays] an important role in the procreation and people will opt for this,” he adds.

 


0

TriNet sent remote workers an email that some thought was a phishing attack

00:23 | 18 November

It was the one of the best phishing emails we’ve seen… that wasn’t.

Phishing remains one of the most popular attack choices for scammers. Phishing emails are designed to impersonate companies or executives to trick users into turning over sensitive information, typically usernames and passwords, so that scammers can log into online services and steal money or data. But detecting and preventing phishing isn’t just a user problem — it’s a corporate problem too, especially when companies don’t take basic cybersecurity precautions and best practices to hinder scammers from ever getting into a user’s inbox.

Enter TriNet, a human resources giant, which this week became the poster child for how how to make a genuine email to its customers look inadvertently as suspicious as it gets.

Remote employees at companies across the U.S. who rely on TriNet for access to outsourced human resources, like their healthcare benefits and workplace policies, were sent an email this week as part of an effort to keep employees “informed and up-to-date on the labor and employment laws that affect you.”

Workers at one Los Angeles-based health startup that manages its employee benefits through TriNet all got the email at the same time. But one employee wasn’t convinced it was a real email, and forwarded it — and its source code — to TechCrunch.

TriNet is one of the largest outsourced human resources providers in the United States, primarily for small-to-medium-sized businesses that may not have the funding to hire dedicated human resources staff. And this time of year is critical for companies that rely on TriNet, since health insurance plans are entering open enrollment and tax season is only a few weeks away. With benefit changes to consider, it’s not unusual for employees to receive a rash of TriNet-related emails towards the end of the year.

But this email didn’t look right. In fact when we looked under the hood of the email, everything about it looked suspicious.

This is the email that remote workers received. TriNet said the use of an Imgur-hosted image in the email was “mistakenly” used. (Image: TechCrunch/supplied)

We looked at the source code of the email, including its headers. These email headers are like an envelope — they say where an email came from, who it’s addressed to, how it was routed, and if there were any complications along the way, such as being marked as spam.

There were more red flags than we could count.

Chief among the issues were that the TriNet logo in the email was hosted on Imgur, a free image-hosting and meme-sharing site, and not the company’s own website. That’s a common technique among phishing attackers — they use Imgur to host images they use in their spam emails to avoid detection. Since the image was uploaded in July, that logo was viewed more than 70,000 times until we reached out to TriNet, which removed the image, suggesting thousands of TriNet customers had received one of these emails. And, although the email contained a link to a TriNet website, the page that loaded had an entirely different domain with nothing on it to suggest it was a real TriNet-authorized site besides a logo, which if it were a phishing site could’ve been easily spoofed.

Fearing that somehow scammers had sent out a phishing email to potentially thousands of TriNet customers, we reached out to security researcher John Wethington, founder of security firm Condition:Black, to examine the email.

It turns out he was just as convinced as us that the email may have been fake.

“As hackers and self-proclaimed social engineers, we often think that spotting a phishing email is ‘easy’,” said Wethington. “The truth is it’s hard.”

“When we first examined the email every alarm bell was going off. The deeper we dug into it the more confusing things became. We looked at the domain name records, the site’s source code, and even the webpage hashes,” he said.

There was nothing, he said, that gave us “100% confidence” that the site was genuine until we contacted TriNet.

TriNet spokesperson Renee Brotherton confirmed to TechCrunch that the email campaign was legitimate, and that it uses the third-party site “for our compliance ePoster service offering. She added: “The Imgur image you reference is an image of the TriNet logo that Poster Elite mistakenly pointed to and it has since been removed.”

“The email you referenced was sent to all employees who do not go into an employer’s physical workspace to ensure their access to required notices,” said TriNet’s spokesperson.

When reached, Poster Elite also confirmed the email was legitimate.

This is not a phishing site, but it sure looks like one. (Image: TechCrunch)

How did TriNet get this so wrong? This culmination of errors had some who received the email worried that their information might have been breached.

“When companies communicate with customers in ways that are similar to the way scammers communicate, it can weaken their customer’s ability over time to spot and shut down security threats in future communications,” said Rachel Tobac, a hacker, social engineer, and founder of SocialProof Security.

Tobac pointed to two examples of where TriNet got it wrong. First, it’s easy for hackers to send spoofed emails to TriNet’s workers because TriNet’s DMARC policy on its domain name is not enforced.

Second, the inconsistent use of domain names is confusing for the user. TriNet confirmed that it pointed the link in the email — posters.trinet.com — to eposterservice.com, which hosts the company’s compliance posters for remote workers. TriNet thought that forwarding the domain would suffice, but instead we thought someone had hijacked TriNet’s domain name settings — a type of attack that’s on the increase, though primarily carried out by state actors. TriNet is a huge target — it stores workers’ benefits, pay details, tax information and more. We had assumed the worst.

“This is similar to an issue we see with banking fraud phone communications,” said Tobac. “Spammers call bank customers, spoof the bank’s number, and pose as the bank to get customers to give account details to ‘verify their account’ before ‘hearing about the fraud the bank noticed on their account — which, of course, is an attack,” she said.

“This is surprisingly exactly what the legitimate phone call sounds like when the bank is truly calling to verify fraudulent transactions,” Tobac said.

Wethington noted that other suspicious indicators were all techniques used by scammers in phishing attacks. The posters.trinet.com subdomain used in the email was only set up a few weeks ago, and the eposterservice.com domain it pointed to used an HTTPS certificate that wasn’t associated with either TriNet or Poster Elite.

These all point to one overarching problem. TriNet may have sent out a legitimate email but everything about it looked problematic.

On one hand, being vigilant about incoming emails is a good thing. And while it’s a cat-and-mouse game to evade phishing attacks, there are things that companies can do to proactively protect themselves and their customers from scams and phishing attacks. And yet TriNet failed in almost every way by opening itself up to attacks by not employing these basic security measures.

“It’s hard to distinguish the good from the bad even with proper training, and when in doubt I recommend you throw it out,” said Wethington.

 


0

Apple Research app arrives on iPhone and Apple Watch with three opt-in health studies

17:37 | 14 November

Apple in September announced its plans for a research app that would allow U.S. consumers to participate in health studies from their Apple devices. Today, that app has gone live for both iPhone and Apple Watch for customers in the U.S. From the new app, Apple Research, users can currently opt to participate in three health studies, including a women’s health study, hearing study, and a heart and movement study.

Apple had teamed up with researchers and health organizations on previous studies, but those would require participants to install a dedicated app on their iOS device for each study alone. The new Research app instead offers a dedicated place for this opt-in activity and makes it simpler for people who want to join multiple studies at once.

The data collected from Apple devices (and their numerous sensors) offers researchers the ability to conduct large-scale health studies in a way that hasn’t been possible before. Before, these sorts of studies were expensive and time-consuming, Apple says, but now users can opt into sharing health-related information directly with researchers — like signals from their heart, motion level and activity, and sound exposure.

Apple’s privacy promises come into play here as well, as it puts data-sharing in users’ control, and offers commitments that data will be encrypted, won’t be sold, and that studies have to inform users how your data will support their research. Participants can also withdraw at any time.

Among the first three studies is a women’s health study in partnership with the Harvard T.H. Chan School of Public Health and National Institute of Environmental Health Sciences. It aims to advance understanding of women’s menstrual cycles and their relationship to infertility, osteoporosis, menopause, and polycystic ovary syndrome (PCOS). This will collect users’ cycle tracking logs from the Health app on the iPhone or the Cycle Tracking app on Apple Watch.

Another heart and movement study is in partnership with the American Heart Association and Brigham and Women’s Hospital, and will use Apple Watch data collected during workouts, plus heart rate and activity data, along with short surveys. This data will be used to understand how certain mobility signals and details about heart rate and rhythm could serve as potential early warning signs of atrial fibrillation (AFib), heart disease or declining mobility, among other things.

The hearing study from the University of Michigan and the World Health Organization collects data about users’ sound exposure from the iPhone and Noise app on Apple Watch, along with surveys and hearing tests. The study will also test if Health app notifications will encourage users to modify their listening behavior, when loud sounds are detected.

“Today marks an important moment as we embark on research initiatives that may offer incredible learnings in areas long sought after by the medical community,” said Jeff Williams, Apple’s chief operating officer, in a statement about the app’s launch. “Participants on the Research app have the opportunity to make a tremendous impact that could lead to new discoveries and help millions lead healthier lives.”

The Research app is rolling out now to iPhone and Apple Watch in the U.S.

 


0

UCLA now has the first zero-emission, all-electric mobile surgical instrument lab

21:46 | 12 November

Electrification in the automotive industry isn’t just about consumer cars: There are plenty of commercial and specialist vehicles that are prime candidates for EVs, including in the healthcare industry. Take the new UCLA mobile surgical lab developed by Winnegbago, for instance – it’s a zero-emission, all-electric vehicle that will move back and forth between two UCLA campuses, collecting, sterilizing and repairing surgical instruments for the medical staff there.

Why is that even needed? The usual process is sending out surgical instruments for this kind of service by a third-party, and it’s handled in a dedicated facility at a significant annual cost. UCLA Health Center estimates that it can save as much as $750,000 per year using the EV lab from Winnebago instead.

The traveling lab can operate for around eight hours, including round-trips between the two hospital campuses, or for a total distance traveled of between 85 and 125 miles on a single charge of its battery, depending on usage. It also offers “the same level of performance, productivity and compliance” as a lab in afixed location building, according to Winnebago.

Aside from annual savings on operating costs, UCLA also got some discounts towards the purchase of the lab from a few grant programs, including the Hybrid and Zero-Emission Truck and and Bus Voucher Incentive Project (an admitted mouthful, but it does have its own acronym luckily – HVIP). These programs all encourage the adoption of electric vehicles through financial incentives that help defray the upfront costs, which is yet another good reason for industries like health care to look at EVs as a way to not only reduce costs long-term, but up-front as well.

 


0

No one knows how effective digital therapies are, but a new tool from Elektra Labs aims to change that

17:28 | 12 November

Depending on which study you believe, the wearable and digital health market could be worth anywhere from $30 billion to nearly $90 billion in the next six years.

If the numbers around the size of the market are a moving target, just think about how to gauge the validity and efficacy of the products that are behind all of those billions of dollars in spending.

Andy Coravos, the co-founder of Elektra Labs, certainly has.

Coravos, whose parents were a dentist and a nurse practitioner, has been thinking about healthcare for a long time. After a stint in private equity and consulting, she took a coding bootcamp and returned to the world she was raised in by taking an internship with the digital therapeutics company, Akili Interactive.

Coravos always thought she wanted to be in healthcare, but there was one thing holding her back, she says. “I’m really bad with blood.”

That’s why digital therapeutics made sense. The stint at Akili led to a position at the U.S. Food and Drug Administration as an entrepreneur in residence, which led to the creation of Elektra Labs roughly two years ago.

Now the company is launching Atlas, which aims to catalog the biometric monitoring technologies that are flooding the consumer health market.

These monitoring technologies, and the applications layered on top of them, have profound implications for consumer health, but there’s been no single place to gauge how effective they are, or whether the suggestions they’re making about how their tools can be used are even valid. Atlas and Elektra are out to change that. 

The FDA has been accelerating its clearances for software-driven products like the atrial fibrillation detection algorithm on the Apple Watch and the ActiGraph activity monitors. And big pharma companies like Roche, Pfizer and Novartis have been investing in these technologies to collect digital biomarker data and improve clinical trials.

Connected technologies could provide better care, but the technologies aren’t without risks. Specifically the accuracy of data and the potential for bias inherent in algorithms which were created using flawed datasets mean that there’s a lot of oversight that still needs to be done, and consumers and pharmaceutical companies need to have a source of easily accessible data about the industry.

”The increase in FDA clearances for digital health products coupled with heavy investment in technology has led to accelerated adoption of connected tools in both clinical trials and routine care. However, this adoption has not come without controversy,” said Coravos, co-founder and CEO of Elektra Labs, in a statement. “During my time as an Entrepreneur in Residence in the FDA’s Digital Health Unit, it became clear to me that like pharmacies which review, prepare, and dispense drug components, our healthcare system needs infrastructure to review, prepare, and dispense connected technologies components.

The analogy to a pharmacy isn’t an exact fit, because Elektra Labs currently doesn’t prepare or dispense any of the treatments that it reviews. But Atlas is clearly the first pillar that the digital therapeutics industry needs as it looks to supplant pharmaceuticals as treatments for some of the largest and most expensive chronic conditions (like diabetes).

Coravos and here team interviewed more than 300 professionals as they built the Atlas toolkit for pharmaceutical companies and other healthcare stakeholders seeking a one-stop-shop for all of their digital healthcare data needs. Like a drug label, or nutrition label, Atlas publishes labels that highlight issues around the usability, validation, utility, security and data governance of a product.

In an article in Quartz earlier this year, Coravos made her pitch for Elektra Labs and the types of things it would monitor for the nascent digital therapeutics industry. It includes the ability to handle adverse events involving digital therapies by providing a single source where problems could be reported; a basic description for consumers of how the products work; an assessment of who should actually receive digital therapies, based on the assessment of how well certain digital products perform with certain users; a description of a digital therapy’s provenance and how it was developed; a database of the potential risks associated with the product; and a record of the product’s security and privacy features.

As the projections on market size show, the problem isn’t going to get any smaller. As Google’s recent acquisition bid for FitBit and the company’s reported partnership with Ascension on “Project Nightingale” to collect and digitize more patient data shows, the intersection of technology and healthcare is a huge opportunity for technology companies.

“Google is investing more. Apple is investing more… More and more of these devices are getting FDA cleared and they’re becoming not just wellness tools but healthcare tools,” says Coravos of the explosion of digital devices pitching potential health and wellness benefits.

Elektra Labs is already working with undisclosed pharmaceutical companies to map out the digital therapeutic environment and identify companies that might be appropriate partners for clinical trials or acquisition targets in the digital market.

“The FDA is thinking about these digital technologies, but there were a lot of gaps,” says Coravos. And those gaps are what Elektra Labs is designed to fill. 

At its core, the company is developing a catalog of the digital biomarkers that modern sensing technologies can track and how effective different products are at providing those measurements. The company is also on the lookout for peer-reviewed published research or any clinical trial data about how effective various digital products are.

Backing Coravos and her vision for the digital pharmacy of the future are venture capital investors including Maverick Ventures, Arkitekt Ventures, Boost VC, Founder Collective, Lux Capital, SV Angel, and Village Global.

Alongside several angel investors, including the founders and chief executives from companies including: PillPack, Flatiron Health, National Vision, Shippo, Revel and Verge Genomics, the venture investors pitched in for a total of $2.9 million in seed funding for Coravos’ latest venture.

“Timing seems right for what Elektra is building,” wrote Brandon Reeves, an investor at Lux Capital, which was . one of the first institutional investors in the company. “We have seen the zeitgeist around privacy data in applications on mobile phones and now starting to have the convo in the public domain about our most sensitive data (health).” 

If the validation of efficacy is one key tenet of the Atlas platform, then security is the other big emphasis of the company’s digital therapeutic assessment.  Indeed, Coravos believes that the two go hand-in-hand. As privacy issues proliferate across the internet, Coravos believes that the same troubles are exponentially compounded by internet-connected devices that are monitoring the most sensitive information that a person has — their own health records.

In an article for Wired, Koravos wrote:

Our healthcare system has strong protections for patients’ biospecimens, like blood or genomic data, but what about our digital specimens? Due to an increase in biometric surveillance from digital tools—which can recognize our face, gait, speech, and behavioral patterns—data rights and governance become critical. Terms of service that gain user consent one time, upon sign-up, are no longer sufficient. We need better social contracts that have informed consent baked into the products themselves and can be adjusted as user preferences change over time.

We need to ensure that the industry has strong ethical underpinning as it brings these monitoring and surveillance tools into the mainstream. Inspired by the Hippocratic Oath—a symbolic promise to provide care in the best interest of patients—a number of security researchers have drafted a new version for Connected Medical Devices.

With more effective regulations, increased commercial activity, and strong governance, software-driven medical products are poised to change healthcare delivery. At this rate, apps and algorithms have the opportunity to augment doctors and complement—or even replace—drugs sooner than we think.

 


0

Facebook finally lets you banish nav bar tabs & red dots

22:43 | 11 November

Are those red notification dots on your Facebook home screen driving you crazy? Sick of Facebook Marketplace wasting your screen space? Now you can control what appears in the Facebook app’s navigation bar thanks to a new option called Shortcuts Bar Settings.

Over the weekend TechCrunch spotted the option to remove certain tabs like Marketplace, Watch, Groups, Events, and Dating or just silence their notification dots. In response to our inquiry, Facebook confirms that Shortcut Bar Settings is now rolling out to everyone, with most iOS users already equipped and the rest of Android owners getting it in the next few weeks.

The move could save the sanity and improve the well-being of people who don’t want their Facebook cluttered with distractions. Users already get important alerts that they could actually control via their Notifications tab. Constant red notification counts on the homescreen are an insidious growth hack, trying to pull in people’s attention to random Group feeds, Event wall posts, and Marketplace.

“We are rolling out navigation bar controls to make it easier for people to connect with the things they like and control the notifications they get within the Facebook app” a Facebook spokesperson tells me.

Back in July 2018, Facebook said it would start personalizing the navigation bar based on what utilities you use most. But the navigation bar seemed more intent on promoting features Facebook wanted to be popular like its Craigslist competitor Marketplace, which I rarely use, rather than its long-standing Events feature I access daily.

To use the Shortcuts Bar Settings options, tap and hold on any of the shortcuts in your navigation bar that’s at the bottom of the Facebook homescreen on iOS and the top on Android. You’ll see a menu pop up letting you remove that tab entirely, or leave it but disable the red notification count overlays. That clears space in your nav bar for a more peaceful experience.

You’ll also now find in the three-line More tab -> Settings & Privacy -> Settings -> Shortcuts menu the ability to toggle any of the Marketplace, Groups, Events, and Pages tabs on or off. Eagle-eyed reverse engineering specialist

spotted in June that Facebook was testing Notification Dots settings menu that’s now available too.

A Facebook spokesperson admits people should have the ability to take a break from notifications within the app. They tell me Facebook wanted to give users more control so they can have access to what’s relevant to them.

For all of Facebook’s talk about well-being, with it trying out hiding Like counts in its app and Instagram (this week starting in the US), there’s still plenty of low-hanging fruit. Better batching of Facebook notifications would be a great step, allowing users to get a daily digest of Groups or Events posts rather than a constant flurry. Its Time Well Spent dashboard that counts your minutes on Facebook should also say how many notifications you get of each type, how many you actually open, and let you disable the most common but useless ones right from there.

If Facebook wants to survive long-term, it can’t piss off users by trapping them in an anxiety-inducing hellscape of growth hacks that benefit the company. The app has become bloated and cramped with extra features over the last 15 years. Facebook could get away with more aggressive cross-promotion of some of these forgotten features as long as it empowers us to hide what we hate.

 


0

Microsoft uses AI to diagnose cervical cancer faster in India

16:00 | 9 November

More women in India die from cervical cancer than in any other country. This preventable disease kills around 67,000 women in India every year, more than 25% of the 260,000 deaths worldwide.

Effective screening and early detection can help reduce its incidence, but part of the challenge — and there are several parts — today is that the testing process to detect the onset of the disease is unbearably time-consuming.

This is because the existing methodology that cytopathologists use is time consuming to begin with, but also because there are very few of them in the nation. Could AI speed this up?

At SRL Diagnostics, the largest chain to offer diagnostic services in pathology and radiology in India, we are getting an early look of this. Last year, Microsoft partnered with SRL Diagnostics to co-create an AI Network for Pathology to ease the burden of cytopathologists and histopathologists.

SRL Diagnostics receives more than 100,000 Pap smear samples every year. About 98% of these samples are typically normal and only the remaining 2% samples require intervention. “We were looking for ways to ensure our cytopathologists were able to find those 2% abnormal samples faster,” explained Dr. Arnab Roy, Technical Lead for New Initiatives & Knowledge Management at SRL Diagnostics.

Cytopathologists at SRL Diagnostics studied digitally scanned versions of Whole Slide Imaging (WSI) slides, each comprising about 300-400 cells, manually and marked their observations, which were used as training data for Cervical Cancer Image Detection API.

A digitally scanned version of a Whole Slide Imaging (WSI) slide, which is used to train the AI model

Then there was the challenge of subjectivity. “Different cytopathologists examine different elements in a smear slide in a unique manner even if the overall diagnosis is the same. This is the subjectivity element in the whole process, which many a time is linked to the experience of the expert,” reveals Dr. Roy.

Manish Gupta, Principal Applied Researcher at Microsoft Azure Global Engineering, who worked closely with the team at SRL Diagnostics, said the idea was to create an AI algorithm that could identify areas that everybody was looking at and “create a consensus on the areas assessed.”

Cytopathologists across multiple labs and locations annotated thousands of tile images of cervical smear. They created discordant and concordant notes on each sample image.

“The images for which annotations were found to be discordant — that is if they were viewed differently by three team members — were sent to senior cytopathologists for final analysis,” Microsoft wrote in a blog post.

This week, the two revealed that their collaboration has started to show results. SRL Diagnostics has started an internal preview to use Cervical Cancer Image Detection API. The Cervical Cancer Image Detection API, which runs on Microsoft’s Azure, can quickly screen liquid-based cytology slide images for detection of cervical cancer in the early stages and return insights to pathologists in labs, the two said.

The AI model can now differentiate between normal and abnormal smear slides with accuracy and is currently under validation in labs for a period of three to six months. It can also classify smear slides based on the seven-subtypes of cervical cytopathological scale, the two wrote in a blog post.

During the internal preview period, the exercise will use more than half-a-million anonymized digital tile images. Following internal validation, the API will be previewed in external cervical cancer diagnostic workflows, including hospitals and other diagnostic centers.

“Cytopathologists now have to review fewer areas, 20 as of now, on a whole slide liquid-based cytology image and validate the positive cases thus bringing in greater efficiency and speeding up the initial screening process,” Microsoft wrote.

“The API has the potential of increasing the productivity of a cytopathology section by about four times. In a future scenario of automated slide preparation with assistance from AI, cytopathologists can do a job in two hours what would earlier take about eight hours!” Dr. Roy said.

SRL Diagnostics-Microsoft consortium said they are hopeful their APIs could find application in other fields of pathology such as diagnosis of kidney pathologies and in oral, pancreatic and liver cancers. The consortium also aims to expand its reach with tie-ups with private players and governments and expand the reach of the model even in remote geographies where the availability of histopathologists is a challenge.

The announcement this week is the latest example of Microsoft’s ongoing research work in India. The world’s second most populous nation has become a test bed for many American technology companies to build new products and services that solve local challenges as they look for their next billion users worldwide.

Last week, Microsoft announced its AI project was helping improve the way driving tests are conducted in India. The company has unveiled a score of tools for the Indian market in the last two years. Microsoft has previously developed tools to help farmers in India increase their crop yields and worked with hospitals to prevent avoidable blindness. Last year, the company partnered with Apollo Hospitals to create an AI-powered API customized to predict risk of heart diseases in India.

Also last year, the company also worked with cricket legend Anil Kumble to develop a tracking device that helps youngsters analyze their batting performance. Microsoft has also tied up with insurance firm ICICI Lombard to help it process customers’ repair claims and renew lapsed policies using an AI system.

 


0

Vape lung ‘breakthrough’ suggests lethal culprit in THC products could be vitamin E acetate

23:23 | 8 November

Official word has come down from federal authorities on one potential cause of the mystery illness affecting vape users: Vitamin E acetate, a chemical found in some vaping products that has been demonstrated to linger in the lungs long afterwards. The finding has been called a “breakthrough” but is far from the last word on the situation.

Sadly, the condition has already claimed the lives of at least 39 people, and more than 2,000 cases have been reported collectively from every state but Alaska. At present the only advice offered has been to stop vaping altogether.

In a media teleconference, the heads of the investigation from the Centers for Disease Control and Prevention explained the basis for pointing the finger at Vitamin E acetate. The substance was cited as a possible problem early on but only recent testing has established it as a bona fide suspect, the team explained.

Samples taken from the lungs of 29 victims of the condition were sent in from 10 different states, and vitamin E acetate was found in all of them. “These findings provide direct evidence of vitamin E acetate as the primary site of injury within the lungs,” said Anne Schuchat, principal deputy director of the CDC .

Although she agreed that this evidence is a “breakthrough,” she noted that it is at present merely a correlative finding — more research is required to establish causation, namely the mechanism of harm, though other work has been done in that area.

“Previous non-CDC research suggests that when vitamin E acetate is inhaled, it may interfere with normal lung function,” she said.

“It’s important to note that these findings do not rule out other possible compounds or ingredients that may be causing these lung injuries,” she continued. “There may be more than one cause of the outbreak.”

Equally important are the statistics involved with the sources of the substances in question. As mentioned earlier in the investigation, a huge proportion of those suffering from this condition were using THC products, and specifically ones acquired through unregulated channels like street dealers.

The vitamin E acetate may have been added for the purpose of essentially cutting the product, Schuchat mentioned in response to a question on the call.

“That may be done for the illicit purpose, or the profit purpose, of diluting the materials, making it look nice and perhaps not having to use as much THC or other active ingredients,” she said.

Other potentially dangerous chemicals have been identified in vape products when heated and aerosolized, including many that even the creators might not have predicted.

Knowing a potential culprit doesn’t get at the heart of the problem, which would be that this chemical (perhaps among others) has already built up over months or years in the lungs of frequent vape users. Treatment is a parallel line of research, but knowing at least one substance responsible should be helpful.

The CDC’s previous advice still stands, the officials noted: They advise avoiding vaping altogether, since there are very few controls at present over what ingredients are allowed in vape products, and what must be declared on the packaging, or indeed whether those declarations are in any way accurate.

 


0

A look at the top trends exciting NYC’s consumer VCs

19:09 | 8 November

To learn more about the next wave of consumer startup investment outside Silicon Valley, I’m speaking to leading B2C-focused investors in various hubs about the trends they’re excited about right now. 

Recently, I shared the responses from several London-based investors; today, we spoke to eight of New York’s top consumer VCs:

  • Rebecca Kaden, Partner at Union Square Ventures
  • David Tisch, Founding Partner at BoxGroup
  • Anu Duggal, Founding Partner at Female Founders Fund
  • Craig Shapiro, Partner at Collaborative Fund
  • Jeremy Levine, Partner at Bessemer
  • Beth Ferreira, Partner at Firstmark Capital
  • Graham Brown, Partner at Lerer Hippeau Ventures
  • Eric Reiner, Partner at Sinai Ventures
  • Chris Paik, Partner at Pace Capital

Consumer health and banking startups were recurring areas of interest, and there’s a sense that apps and product brands which provide a deeper sense of community are an untapped opportunity.

Rebecca Kaden, Partner at Union Square Ventures

At USV, we are focused on opportunities that broaden access by leveraging technology to increase value and decrease cost in big buckets of consumer spend. In doing so, we are looking for ways to make products and services previously available to a select segment available to many more. In particular, we have been investing in areas of consumer health where the delivery mechanism not only makes the care more convenient but also more affordable and higher quality; products and platforms in financial services that change the traditional underlying model to drive financial health for a mass customer; and opportunities that create new access to education both for kids and lifelong learners. 

Within each of these segments, I’ve been very interested in how new communities are forming inside products–users that come for a specific offering are forming allegiance and increasing engagement by interacting with other users. I think that is a trend we will only see accelerate.

David Tisch, Founding Partner at BoxGroup

People are bored on their phones, not of their phones. I am most excited to meet founders working on consumer apps that bring happiness and fun to a mass consumer audience, as I continue to believe we are in the early days of mobile and the app store is not dead.

These apps may look like a game, they may be a game, or they may be a new feed, but TikTok, Twitch, HQ, Yolo and other Snap app kit apps, Tinder and others have shown consumers want new apps, the barrier for adoption and retention is  just very high. All apps and games have a half-life, creating something with a very long one is really hard, but the demand is sitting on the phone scrolling thorough feeds, waiting for some new fun. We are excited about apps that allow people to interact with others in different ways, in new worlds, using new hardware, or new interfaces.

Anu Duggal, Founding Partner at Female Founders Fund

With the rise of the sober curious movement, we invested in Kin Euphorics, offering consumers a sexy option to an alcoholic drink, creating a social experience around a non-alcoholic beverage that doesn’t exist in the market today. With beer sales decreasing five years in a row, brands like Heineken are offering alcohol-free alternatives catering to this growing audience.

With the decline of religion, we have seen the rise of what we call the “rise of the alternate community.” Consumers are looking for ways to connect online and offline based on specific interests. Examples of this in our portfolio include The Wonder, a membership model for familyhood, Peanut, a social network for modern motherhood, and Co-Star, an astrology app.

 


0

DNA testing startup Veritas Genetics confirms data breach

00:13 | 8 November

Veritas Genetics, a DNA testing startup, has said a data breach resulted in the theft of some customer information.

The Danvers, MA-based company said its customer facing portal had “recently” been breached but did not say when. Although the portal did not contain test results or medical information, the company declined to say what information had been stolen — only that a handful of customers were affected.

The company has not issued a public statement, nor has it acknowledge the breach on its website. A spokesperson for Veritas did not respond to a request for comment.

Bloomberg first reported the news.

Veritas, whose competitors include 23andMe, Ancestry, and MyHeritage, says it can analyze and understand a human genome using a smaller portion of an individual’s DNA, allowing customers to better understand what health risks they may face in later life or pass on to their children.

Although the stolen data did not include personal health information, it’s likely to further fuel concerns that health startups, particularly companies dealing with sensitive DNA and genome information, can’t protect their users’ data.

Privacy remains an emerging concern in genetics testing after law enforcement have served legal demands against DNA collection and genetics testing companies to help identify suspects in criminal cases. Just this week, it was reported that a “game changer” warrant obtained in Florida allowed one police department to search the full database of GEDmatch, a DNA testing company, which was last year was used by police to help catch the notorious Golden State Killer.

Some 26 million consumers have used an at-home genetics testing kit.

 


0
<< Back Forward >>
Topics from 1 to 10 | in all: 60

Site search


Last comments

Walmart retreats from its UK Asda business to hone its focus on competing with Amazon
Peter Short
Good luck
Peter Short

Evolve Foundation launches a $100 million fund to find startups working to relieve human suffering
Peter Short
Money will give hope
Peter Short

Boeing will build DARPA’s XS-1 experimental spaceplane
Peter Short
Great
Peter Short

Is a “robot tax” really an “innovation penalty”?
Peter Short
It need to be taxed also any organic substance ie food than is used as a calorie transfer needs tax…
Peter Short

Twitter Is Testing A Dedicated GIF Button On Mobile
Peter Short
Sounds great Facebook got a button a few years ago
Then it disappeared Twitter needs a bottom maybe…
Peter Short

Apple’s Next iPhone Rumored To Debut On September 9th
Peter Short
Looks like a nice cycle of a round year;)
Peter Short

AncestryDNA And Google’s Calico Team Up To Study Genetic Longevity
Peter Short
I'm still fascinated by DNA though I favour pure chemistry what could be
Offered is for future gen…
Peter Short

U.K. Push For Better Broadband For Startups
Verg Matthews
There has to an email option icon to send to the clowns in MTNL ... the govt of India's service pro…
Verg Matthews

CrunchWeek: Apple Makes Music, Oculus Aims For Mainstream, Twitter CEO Shakeup
Peter Short
Noted Google maybe grooming Twitter as a partner in Social Media but with whistle blowing coming to…
Peter Short

CrunchWeek: Apple Makes Music, Oculus Aims For Mainstream, Twitter CEO Shakeup
Peter Short
Noted Google maybe grooming Twitter as a partner in Social Media but with whistle blowing coming to…
Peter Short